Amgen Inc.

NASDAQ

Market Cap.

151.96B

Avg. Volume

3.25M

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

AI Generated Qualitative Analysis

AI

Your time is precious, so save it. Use AI to get the most important information from the business.

Learn about Amgen Inc.

Amgen Inc. News

Amgen Inc. Quantitative Score

Overall Score

Business

Growth

Unlock

Business

Quality

Unlock

Stock

Value

Unlock

Price

Move

Price

Momentum

Unlock

Price

Stability

Unlock
Website screenshot
HealthcareDrug Manufacturers - General
amgen.com

About Amgen Inc.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Amgen Inc. Earnings & Revenue

Amgen Inc. Financials

Table Compare

Compare AMGN metrics with:

   

Earnings & Growth

AMGN

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

AMGN

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

AMGN

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

AMGN

None

Debt/Assets Ratio

--

--

Assets/Liabilities Ratio

--

--

 

Amgen Inc. Income

Amgen Inc. Balance Sheet

Amgen Inc. Cash Flow

Amgen Inc. Financials Over Time

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsStrong Buy
Return on EquityStrong Buy
Return on AssetsStrong Buy
Debt/Equity RatioStrong Sell
Price/Earnings RatioStrong Sell
Price/Book RatioStrong Sell

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Amgen Inc. Dividends

Yield (TTM)Dividend (TTM) 

Infinity%

9.2600

Payment DateDividendFrequency
2025-06-062.38Quarterly
2025-03-072.38Quarterly
2024-12-092.25Quarterly
2024-09-062.25Quarterly
2024-06-072.25Quarterly

Amgen Inc. Valuation

Project future cash flows and get the intrinsic value per share.

Start valuation modeling

Historical Market Cap

Shares Outstanding

Amgen Inc. Executives

NameRole
Mr. Robert A. BradwayChairman, Chief Executive Officer & President
Dr. James E. Bradner M.D.Executive Vice President of Research & Development
Dr. David M. Reese M.D.Executive Vice President & Chief Technology Officer
Mr. Murdo GordonExecutive Vice President of Global Commercial Operations
Mr. Peter H. GriffithExecutive Vice President & Chief Financial Officer
NameRoleGenderDate of BirthPay
Mr. Robert A. BradwayChairman, Chief Executive Officer & PresidentMale19636.43M
Dr. James E. Bradner M.D.Executive Vice President of Research & Development19724.1M
Dr. David M. Reese M.D.Executive Vice President & Chief Technology Officer19633.33M
Mr. Murdo GordonExecutive Vice President of Global Commercial OperationsMale19673.17M
Mr. Peter H. GriffithExecutive Vice President & Chief Financial OfficerMale19593.01M

Amgen Inc. Insider Trades

Date17 Mar
NameSantos Esteban
RoleEVP, Operations
TransactionDisposed
TypeF-InKind
Shares3393
Date17 Mar
NameREESE DAVID M
RoleEVP & Chief Technology Officer
TransactionDisposed
TypeF-InKind
Shares3635
Date17 Mar
NameMiller Derek
RoleSVP, Human Resources
TransactionDisposed
TypeF-InKind
Shares930
Date17 Mar
NameKhosla Rachna
RoleSVP, Business Development
TransactionDisposed
TypeF-InKind
Shares489
Date17 Mar
NameGrygiel Nancy A.
RoleSVP & CCO
TransactionDisposed
TypeF-InKind
Shares524
DateNameRoleTransactionTypeShares
17 MarSantos EstebanEVP, OperationsDisposedF-InKind3393
17 MarREESE DAVID MEVP & Chief Technology OfficerDisposedF-InKind3635
17 MarMiller DerekSVP, Human ResourcesDisposedF-InKind930
17 MarKhosla RachnaSVP, Business DevelopmentDisposedF-InKind489
17 MarGrygiel Nancy A.SVP & CCODisposedF-InKind524

Discover More

Streamlined Academy

Amgen Inc.

NASDAQ

Market Cap.

151.96B

Avg. Volume

3.25M

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

Amgen Inc. News

Amgen Inc. Quantitative Score

Overall Score

Business

Growth

Unlock

Business

Quality

Unlock

Stock

Value

Unlock

Price

Move

Price

Momentum

Unlock

Price

Stability

Unlock

Amgen Inc. Earnings & Revenue

Amgen Inc. Income

Amgen Inc. Balance Sheet

Amgen Inc. Cash Flow

Amgen Inc. Financials Over Time

Amgen Inc. Executives

NameRole
Mr. Robert A. BradwayChairman, Chief Executive Officer & President
Dr. James E. Bradner M.D.Executive Vice President of Research & Development
Dr. David M. Reese M.D.Executive Vice President & Chief Technology Officer
Mr. Murdo GordonExecutive Vice President of Global Commercial Operations
Mr. Peter H. GriffithExecutive Vice President & Chief Financial Officer
NameRoleGenderDate of BirthPay
Mr. Robert A. BradwayChairman, Chief Executive Officer & PresidentMale19636.43M
Dr. James E. Bradner M.D.Executive Vice President of Research & Development19724.1M
Dr. David M. Reese M.D.Executive Vice President & Chief Technology Officer19633.33M
Mr. Murdo GordonExecutive Vice President of Global Commercial OperationsMale19673.17M
Mr. Peter H. GriffithExecutive Vice President & Chief Financial OfficerMale19593.01M

Amgen Inc. Insider Trades

Date17 Mar
NameSantos Esteban
RoleEVP, Operations
TransactionDisposed
TypeF-InKind
Shares3393
Date17 Mar
NameREESE DAVID M
RoleEVP & Chief Technology Officer
TransactionDisposed
TypeF-InKind
Shares3635
Date17 Mar
NameMiller Derek
RoleSVP, Human Resources
TransactionDisposed
TypeF-InKind
Shares930
Date17 Mar
NameKhosla Rachna
RoleSVP, Business Development
TransactionDisposed
TypeF-InKind
Shares489
Date17 Mar
NameGrygiel Nancy A.
RoleSVP & CCO
TransactionDisposed
TypeF-InKind
Shares524
DateNameRoleTransactionTypeShares
17 MarSantos EstebanEVP, OperationsDisposedF-InKind3393
17 MarREESE DAVID MEVP & Chief Technology OfficerDisposedF-InKind3635
17 MarMiller DerekSVP, Human ResourcesDisposedF-InKind930
17 MarKhosla RachnaSVP, Business DevelopmentDisposedF-InKind489
17 MarGrygiel Nancy A.SVP & CCODisposedF-InKind524

Streamlined Academy

Website screenshot
HealthcareDrug Manufacturers - General
amgen.com

About Amgen Inc.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

AI Generated Qualitative Analysis

AI

Your time is precious, so save it. Use AI to get the most important information from the business.

Learn about Amgen Inc.

Amgen Inc. Financials

Table Compare

Compare AMGN metrics with:

   

Earnings & Growth

AMGN

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

AMGN

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

AMGN

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

AMGN

None

Debt/Assets Ratio

--

--

Assets/Liabilities Ratio

--

--

 

Amgen Inc. Dividends

Yield (TTM)Dividend (TTM) 

Infinity%

9.2600

Payment DateDividendFrequency
2025-06-062.38Quarterly
2025-03-072.38Quarterly
2024-12-092.25Quarterly
2024-09-062.25Quarterly
2024-06-072.25Quarterly

Amgen Inc. Valuation

Project future cash flows and get the intrinsic value per share.

Start valuation modeling

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsStrong Buy
Return on EquityStrong Buy
Return on AssetsStrong Buy
Debt/Equity RatioStrong Sell
Price/Earnings RatioStrong Sell
Price/Book RatioStrong Sell

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Historical Market Cap

Shares Outstanding

Discover More

A Practical Guide: How To Analyze Any Stock (With Examples)